Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Burden and Prevention of HPV. Knowledge, Practices and Attitude Assessment Among Pre-Adolescents and their Parents in Italy

Author(s): Giancarlo Icardi, Claudio Costantino, Marcello Guido, Antonella Zizza, Vincenzo Restivo, Daniela Amicizia, Federico Tassinari, Maria Francesca Piazza, Chiara Paganino, Alessandra Casuccio, Francesco Vitale, Filippo Ansaldi and Cecilia Trucchi*

Volume 26, Issue 3, 2020

Page: [326 - 342] Pages: 17

DOI: 10.2174/1381612826666200114100553

open access plus

Abstract

Despite infections due to HPV nowadays represent the most common sexually transmitted diseases worldwide with recognized effective and safe preventive strategies, knowledge, attitudes; however, awareness on HPV is considerably low. The present study has two main objectives: 1. To conduct a literature review to analyze the evolution of preventive tools, the complexity of the vaccine choice process, and the challenges posed by HPV vaccine hesitancy and refusal among pre-adolescents and their parents; 2. To assess knowledge, practices and attitudes toward HPV infection and vaccination in a sample of Italian pre-adolescents and their parents. The observational study was carried out through the use of two anonymous and self-administered pre- and postintervention questionnaires dedicated to the target populations. Between the administrations of the pre- and postintervention questionnaires, an educational intervention on HPV infection and related diseases, and prevention strategies was conducted. All participants demonstrated suboptimal knowledge and positive attitudes in the preintervention questionnaire. Higher levels of knowledge and attitudes were observed among pre-adolescents thatused social networks and had heard of sexually transmitted diseases at home/school/physician and from parents and also who had heard of HPV from General Practitioners, Gynecologists, family members and newspapers. A significant increase in HPV vaccination awareness was observed among pre-adolescents after the educational sessions. Health education programs aimed at increasing knowledge, attitudes and awareness on HPV are needed to implement the outcomes of HPV immunization programs, especially if supported by the physicians involved in counselling and recommendation processes.

Keywords: HPV, knowledge, practice, attitude, adolescents, parents, vaccine.

« Previous Next »
[1]
Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014; 41(11): 660-4.
[http://dx.doi.org/10.1097/OLQ.0000000000000193] [PMID: 25299412]
[2]
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202(12): 1789-99.
[http://dx.doi.org/10.1086/657321] [PMID: 21067372]
[3]
Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158(5): 486-94.
[http://dx.doi.org/10.1093/aje/kwg171] [PMID: 12936904]
[4]
Toh ZQ, Kosasih J, Russell FM, Garland SM, Mulholland EK, Licciardi PV. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist 2019; 12: 1951-67.
[http://dx.doi.org/10.2147/IDR.S178381] [PMID: 31308715]
[5]
de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013; 445(1-2): 2-10.
[http://dx.doi.org/10.1016/j.virol.2013.04.023] [PMID: 23683837]
[6]
Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337(1): 76-84.
[http://dx.doi.org/10.1016/j.virol.2005.04.002] [PMID: 15914222]
[7]
Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199(6): 805-14.
[http://dx.doi.org/10.1086/597071] [PMID: 19199546]
[8]
Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13: 39.
[http://dx.doi.org/10.1186/1471-2334-13-39] [PMID: 23347441]
[9]
Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010; 118(6-7): 450-4.
[http://dx.doi.org/10.1111/j.1600-0463.2010.02619.x] [PMID: 20553527]
[10]
Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016; 2: 16086.
[http://dx.doi.org/10.1038/nrdp.2016.86] [PMID: 27905473]
[11]
Fortes HR, von Ranke FM, Escuissato DL, et al. Recurrent respiratory papillomatosis: A state-of-the-art review. Respir Med 2017; 126: 116-21.
[http://dx.doi.org/10.1016/ j.rmed.2017.03.030] [PMID: 28427542]
[12]
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016; 4(9): e609-16.
[http://dx.doi.org/10.1016/S2214-109X(16)30143-7] [PMID: 27470177]
[13]
Bruni L, Albero G, Serrano B, et al. CO/IARC Information centre on HPV and cancer (HPV Information Centre) Human papillomavirus and related diseases in the world Summary report 17 June 2019.. https://www.hpvcentre.net/ statistics/ reports/ XWX.pdf
[14]
International Agency for Research on Cancer Cancer Today Lyon, France. http://gco.iarc.fr/today/home
[15]
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017; 141(4): 664-70.
[http://dx.doi.org/10.1002/ijc.30716] [PMID: 28369882]
[16]
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11(11): 1048-56.
[http://dx.doi.org/10.1016/S1470-2045(10)70230-8] [PMID: 20952254]
[17]
de Sanjosé S, Serrano B, Tous S, et al. RIS HPV TT, VVAP and head and neck study groups. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr 2019; 2(4) pky045
[http://dx.doi.org/10.1093/jncics/pky045] [PMID: 31360870]
[18]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[19]
Kent A. HPV Vaccination and testing. Rev Obstet Gynecol 2010; 3(1): 33-4.
[PMID: 20508781]
[20]
Prue G, Baker P, Graham D, Nutting C, Greenhouse P, Lawler M. It is time for universal HPV vaccination. Lancet 2018; 392(10151): 913-4.
[http://dx.doi.org/10.1016/S0140-6736(18)31821-X] [PMID: 30238882]
[21]
Human papillomavirus vaccines: WHO position paper, May 2017 Geneva, Switzerland. 2017.
[22]
Campagna di comunicazione contro il Papilloma Virus-2008 \. http://www.salute.gov.it/portale/news/p3_2_6_1_1.jsp?lingua=italiano&menu=campagne&p=dacampagne&id=42
[23]
Intesa ai sensi dell’articolo 8, comma 6, della legge 5 giugno 2003, n. 131.
[24]
Trucchi C, Costantino C, Restivo V, et al. Immunization campaigns and strategies against human papillomavirus in Italy: the results of a survey to regional and local health units representatives. BioMed Res Int 2019; 2019 6764154
[http://dx.doi.org/10.1155/2019/6764154] [PMID: 31355274]
[25]
Clendinen C, Zhang Y, Warburton RN, Light DW. Manufacturing costs of HPV vaccines for developing countries. Vaccine 2016; 34(48): 5984-9.
[http://dx.doi.org/10.1016/j.vaccine.2016.09.042] [PMID: 27771183]
[26]
Remes P, Selestine V, Changalucha J, et al. A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 2012; 30(36): 5363-7.
[http://dx.doi.org/10.1016/j.vaccine.2012.06.025] [PMID: 22732428]
[27]
LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011; 89(11): 821-30B.
[http://dx.doi.org/10.2471/BLT.11.089862] [PMID: 22084528]
[28]
Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45(2-3): 107-14.
[http://dx.doi.org/10.1016/j.ypmed.2007.05.013] [PMID: 17628649]
[29]
Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine 2013; 31(37): 3811-7.
[http://dx.doi.org/10.1016/j.vaccine.2013.06.016] [PMID: 23777956]
[30]
Toh ZQ, Licciardi PV, Russell FM, Garland SM, Batmunkh T, Mulholland EK. Cervical cancer prevention through HPV vaccination in low- and middle-income countries in Asia. Asian Pac J Cancer Prev 2017; 18(9): 2339-43.
[PMID: 28950675]
[31]
Howard N, Gallagher KE, Mounier-Jack S, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res 2017; 4: 22-5.
[http://dx.doi.org/10.1016/j.pvr.2017.06.003] [PMID: 29179865]
[32]
Coperture vaccinali al 31/12/2017 per HPV . http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=3429
[33]
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356(19): 1915-27.
[http://dx.doi.org/10.1056/NEJMoa061741] [PMID: 17494925]
[34]
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356(19): 1928-43.
[http://dx.doi.org/10.1056/NEJMoa061760] [PMID: 17494926]
[35]
Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493.
[http://dx.doi.org/10.1136/bmj.c3493] [PMID: 20647284]
[36]
Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
[http://dx.doi.org/10.1016/S1470-2045(11)70286-8] [PMID: http://www.ncbi.nlm.nih.gov/pubmed/]
[37]
Mensah FA, Mehta MR, Lewis JS Jr, Lockhart AC. The human papillomavirus vaccine: current perspective and future role in prevention and treatment of anal intraepithelial neoplasia and anal cancer. Oncologist 2016; 21(4): 453-60.
[http://dx.doi.org/10.1634/theoncologist.2015-0075] [PMID: 26961923]
[38]
Summary of product characteristics. https://www.ema.europa.eu/ en/documents/product-information/cervarix-epar-product-information_en.pdf
[39]
Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128(4): 927-35.
[http://dx.doi.org/10.1002/ijc.25396] [PMID: 20473886]
[40]
Brotherton JML, Tabrizi SN, Phillips S, et al. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. Int J Cancer 2017; 141(8): 1576-84.
[http://dx.doi.org/10.1002/ijc.30871] [PMID: 28677147]
[41]
Summary of product characteristics:. https://www.ema.europa.eu/ en/documents/product-information/gardasil-9-epar-product-information_en.pdf
[42]
de Sanjose S, Brotons M, LaMontagne DS, Bruni L. Human papillomavirus vaccine disease impact beyond expectations. Curr Opin Virol 2019; 39: 16-22.
[http://dx.doi.org/10.1016/j.coviro.2019.06.006] [PMID: 31382121]
[43]
Vaccine scheduler-human papillomavirus infection: recommended vaccinations Stockholm: ECDC 2018.http://vaccineschedule.ecdc. europa.eu/Scheduler/ByDisease?SelectedDiseaseId=38
[44]
Public consultation on draft guidance for introduction of HPV vaccines in EU countries:. focus on 9-valent HPV vaccine and vaccination of boys and people living with HIV https://ecdc.europa.eu/ sites/portal/files/documents/hpv-public-consultation-3-April.pdf
[45]
Martakis K, Alexander D, Schloemer T, Blair M, Rigby M, Schröder-Bäck P. Human papillomavirus vaccination and respect for children’s developing autonomy: Results from a European Union wide study. J Child Health Care 2019; 23(3): 343-57.
[http://dx.doi.org/10.1177/1367493519852476] [PMID: 31132868]
[46]
Wallace LA, Bramley JC, Ahmed S, et al. Determinants of universal adolescent hepatitis B vaccine uptake. Arch Dis Child 2004; 89(11): 1041-2.
[http://dx.doi.org/10.1136/adc.2003.043687] [PMID: 15499061]
[47]
Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 2012; 30(24): 3546-56.
[http://dx.doi.org/10.1016/j.vaccine.2012.03.063] [PMID: 22480928]
[48]
Giambi C, Del Manso M, De Mei B, et al. VALORE working group.. VALORE Project: localand regional assessment of vaccination campaigns against HPV: promote conscious adherence to vaccination. Rapporti ISTISAN 13/47 Rome: National Center for Epidemiology Surveillance and Health Promotion (CNESPS) 2013.http://www.iss.it/binary/publ/cont/13_47_web.pdf
[49]
Paterson P, Mounier-Jack S, Saliba V, et al. Strengthening HPV vaccination delivery: findings from a qualitative service evaluation of the adolescent girls’ HPV vaccination programme in England. J Public Health (Oxf) 2019. fdz061
[http://dx.doi.org/10.1093/pubmed/fdz061] [PMID: 31219155]
[50]
Palmeri S, Costantino C, D’Angelo C, et al. HPV vaccine hesitancy among parents of female adolescents: a pre-post interventional study. Public Health 2017; 150: 84-6.
[http://dx.doi.org/10.1016/j.puhe.2017.05.009] [PMID: 28646698]
[51]
Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016; 4(7): e453-63.
[http://dx.doi.org/10.1016/S2214-109X(16)30099-7] [PMID: 27340003]
[52]
Coperture nell’età pediatrica e nell’adolescente . http://www. salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp?lingua=italiano&id=20
[53]
Piano Nazionale Prevenzione Vaccinale 2017-2019.. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf
[54]
Sriram S, Ranganathan R. Why human papilloma virus vaccination coverage is low among adolescents in the US? A study of barriers for vaccination uptake. J Family Med Prim Care 2019; 8(3): 866-70.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_107_19] [PMID: 31041215]
[55]
Jeudin P, Liveright E, Del Carmen MG, Perkins RB. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates. Clin Ther 2014; 36(1): 24-37.
[http://dx.doi.org/10.1016/j.clinthera.2013.11.001] [PMID: 24417783]
[56]
Forster AS, Cornelius V, Rockliffe L, Marlow LA, Bedford H, Waller J. A cluster randomised feasibility study of an adolescent incentive intervention to increase uptake of HPV vaccination. Br J Cancer 2017; 117(8): 1121-7.
[http://dx.doi.org/10.1038/bjc.2017.284] [PMID: 28829766]
[57]
Das JK, Salam RA, Arshad A, Lassi ZS, Bhutta ZA. Systematic review and meta-analysis of interventions to improve access and coverage of adolescent immunizations. J Adolesc Health 2016; 59(4S): S40-8.
[http://dx.doi.org/10.1016/j.jadohealth.2016.07.005] [PMID: 27664595]
[58]
Teeter BS, Mosley C, Thomas JL, et al. Improving HPV vaccination using implementation strategies in community pharmacies: Pilot study protocol. Res Social Adm Pharm 2019; S1551-7411(19): 30555-8.
[http://dx.doi.org/10.1016/j.sapharm.2019.05.022] [PMID: 31174950]
[59]
Islam JY, Gruber JF, Kepka D, et al. Pharmacist insights into adolescent human papillomavirus vaccination provision in the United States. Hum Vaccin Immunother 2019; 15(7-8): 1839-50.
[http://dx.doi.org/10.1080/21645515.2018.1556077] [PMID: 30550369]
[60]
Ruiz-López T, Sen S, Jakobsen E, et al. Fight HPV: design and evaluation of a mobile game to raise awareness about human papillomavirus and nudge people to take action against cervical cancer. JMIR Serious Games 2019; 7(2) e8540
[http://dx.doi.org/10.2196/games.8540] [PMID: 30958271]
[61]
Callaghan T, Motta M, Sylvester S, Lunz Trujillo K, Blackburn CC. Parent psychology and the decision to delay childhood vaccination. Soc Sci Med 2019; 238 112407
[http://dx.doi.org/10.1016/j.socscimed.2019.112407] [PMID: 31366444]
[62]
Di Pietro ML, Poscia A, Teleman AA, Maged D, Ricciardi W. Vaccine hesitancy: parental, professional and public responsibility. Ann Ist Super Sanita 2017; 53(2): 157-62.
[PMID: 28617263]
[63]
Summary WHO. SAGE conclusions and recommendations on vaccine hesitancy Geneva: WHO; January 2015. www.who.int/immunization/programmes_systems/summary_of_sage_vaccinehesitancy_2pager.pdf?ua=1
[64]
Liddon NC, Hood JE, Leichliter JS. Intent to receive HPV vaccine and reasons for not vaccinating among unvaccinated adolescent and young women: findings from the 2006-2008 National Survey of Family Growth. Vaccine 2012; 30(16): 2676-82.
[http://dx.doi.org/10.1016/j.vaccine.2012.02.007] [PMID: 22342548]
[65]
Restivo V, Costantino C, Fazio TF, et al. Factors associated with HPV vaccine refusal among young adult women after ten years of vaccine implementation. Int J Environ Res Public Health 2018; 15(4): 15.
[http://dx.doi.org/10.3390/ijerph15040770] [PMID: 29673135]
[66]
Jean S III, Elshafei M, Buttenheim A. Social determinants of community-level human papillomavirus vaccination coverage in aschool-based vaccination programme. Sex Transm Infect 2018; 94(4): 248-53.
[http://dx.doi.org/10.1136/sextrans-2017-053357] [PMID: 29330310]
[67]
Michail G, Smaili M, Vozikis A, Jelastopulu E, Adonakis G, Poulas K. Female students receiving post-secondary education in Greece: the results of a collaborative human papillomavirus knowledge survey. Public Health 2014; 128(12): 1099-105.
[http://dx.doi.org/10.1016/j.puhe.2014.09.005] [PMID: 25443133]
[68]
Patty NJS, van Dijk HM, Wallenburg I, et al. To vaccinate or not to vaccinate? Perspectives on HPV vaccination among girls, boys, and parents in the Netherlands: a Q-methodological study. BMC Public Health 2017; 17(1): 872.
[http://dx.doi.org/10.1186/s12889-017-4879-2] [PMID: 29115958]
[69]
Istituto Nazionale di Statistica Indicatori demografici.. http://dati.istat.it/Index.aspx?DataSetCode=DCIS_INDDEMOG1
[70]
Cory L, Cha B, Ellenberg S, et al. Effects of educational interventions on human papillomavirus vaccine acceptability: a randomized controlled trial. Obstet Gynecol 2019; 134(2): 376-84.
[http://dx.doi.org/10.1097/AOG.0000000000003379] [PMID: 31306313]
[71]
Liu CR, Liang H, Zhang X, et al. Effect of an educational intervention on HPV knowledge and attitudes towards HPV and its vaccines among junior middle school students in Chengdu, China. BMC Public Health 2019; 19(1): 488.
[http://dx.doi.org/10.1186/s12889-019-6823-0] [PMID: 31046722]
[72]
Herman R, McNutt LA, Mehta M, Salmon DA, Bednarczyk RA, Shaw J. Vaccination perspectives among adolescents and their desired role in the decision-making process. Hum Vaccin Immunother 2019; 15(7-8): 1752-9.
[http://dx.doi.org/10.1080/21645515.2019.1571891] [PMID: 30735440]
[73]
Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health 2009; 45(5): 453-62.
[http://dx.doi.org/10.1016/j.jadohealth.2009.04.021] [PMID: 19837351]
[74]
McRee AL, Reiter PL, Brewer NT. Vaccinating adolescent girls against human papillomavirus-Who decides? Prev Med 2010; 50(4): 213-4.
[http://dx.doi.org/10.1016/j.ypmed.2010.02.001] [PMID: 20153358]
[75]
Xue L, Hu W, Zhang H, et al. Awareness of and willingness to be vaccinated by human papillomavirus vaccine among junior middle school students in Jinan, China. Hum Vaccin Immunother 2018; 14(2): 404-11.
[http://dx.doi.org/10.1080/21645515.2017.1393132] [PMID: 29048994]
[76]
Clark SJ, Cowan AE, Filipp SL, Fisher AM, Stokley S. Parent HPV vaccine perspectives and the likelihood of HPV vaccination of adolescent males. Hum Vaccin Immunother 2016; 12(1): 47-51.
[http://dx.doi.org/10.1080/21645515.2015.1073426] [PMID: 26225463]
[77]
Clark SJ, Cowan AE, Filipp SL, Fisher AM, Stokley S. Parent perception of provider interactions influences HPV vaccination status of adolescent females. Clin Pediatr (Phila) 2016; 55(8): 701-6.
[http://dx.doi.org/10.1177/0009922815610629] [PMID: 26450982]
[78]
Suryadevara M, Bonville JR, Kline RM, et al. Student HPV vaccine attitudes and vaccine completion by education level. Hum Vaccin Immunother 2016; 12(6): 1491-7.
[http://dx.doi.org/10.1080/21645515.2015.1123359] [PMID: 26836052]
[79]
Ortiz RR, Shafer A, Cates J, Coyne-Beasley T. Development and evaluation of a social media health intervention to improve adolescents' knowledge about and vaccination against the human papillomavirus. Glob Pediatr Health 2018; 5 2333794X18777918.
[http://dx.doi.org/10.1177/2333794X18777918] [PMID: 29872667]
[80]
Tabacchi G, Costantino C, Cracchiolo M, et al. Information sources and knowledge on vaccination in a population from southern Italy: The ESCULAPIO project. Hum Vaccin Immunother 2017; 13(2): 339-45.
[http://dx.doi.org/10.1080/21645515.2017.1264733] [PMID: 28032814]
[81]
Facciolà A, Visalli G, Orlando A, et al. Vaccine hesitancy: An overview on parents’ opinions about vaccination and possible reasons of vaccine refusal. J Public Health Res 2019; 8(1): 1436.
[http://dx.doi.org/10.4081/jphr.2019.1436] [PMID: 30997357]
[82]
Perez S, Restle H, Naz A, Tatar O, Shapiro GK, Rosberger Z. Parents’ involvement in the human papillomavirus vaccination decision for their sons. Sex Reprod Healthc 2017; 14: 33-9.
[http://dx.doi.org/10.1016/j.srhc.2017.08.005] [PMID: 29195632]
[83]
Zhu L, Zhai S, Siu PT, et al. Factors related to chinese parents’ HPV vaccination intention for children. Am J Health Behav 2019; 43(5): 994-1005.
[http://dx.doi.org/10.5993/AJHB.43.5.10] [PMID: 31439104]
[84]
Newman PA, Logie CH, Lacombe-Duncan A, et al. Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies. BMJ Open 2018; 8(4) e019206
[http://dx.doi.org/10.1136/bmjopen-2017-019206] [PMID: 29678965]
[85]
Hanson KE, Koch B, Bonner K, McRee AL, Basta NE. National trends in parental human papillomavirus vaccination intentions and reasons for hesitancy, 2010-2015. Clin Infect Dis 2018; 67(7): 1018-26.
[http://dx.doi.org/10.1093/cid/ciy232] [PMID: 29596595]
[86]
Mohammed KA, Vivian E, Loux TM, Arnold LD. Factors associated with parents’ intent to vaccinate adolescents for human papillomavirus: findings from the 2014 national immunization survey-teen. Prev Chronic Dis 2017; 14 E45
[http://dx.doi.org/10.5888/pcd14.160314] [PMID: 28595031]
[87]
Baldovin T, Bertoncello C, Cocchio S, et al. Perception and knowledge of HPV-related and vaccine-related conditions among a large cohort of university students in Italy. Hum Vaccin Immunother 2019; 15(7-8): 1641-9.
[http://dx.doi.org/10.1080/21645515.2018.1564432] [PMID: 30689506]

Rights & Permissions Print Cite
Article Metrics
12
© 2024 Bentham Science Publishers | Privacy Policy